The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies

Jennifer L. Beebe-Dimmer, Matthew Hathcock, Cecilia Yee, Linda A. Okoth, Charles M. Ewing, William B. Isaacs, Kathleen A. Cooney, Stephen N Thibodeau

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: A rare nonconservative substitution (G84E) in the HOXB13 gene has been shown to be associated with risk of prostate cancer. DNA samples from male patients included in the Mayo Clinic Biobank (MCB) were genotyped to determine the frequency of the G84E mutation and its association with various cancers. Methods: Subjects were genotyped using a custom TaqMan (Applied Biosystems) assay for G84E (rs138213197). In addition to donating a blood specimen, all MCB participants completed a baseline questionnaire to collect information on medical history and family history of cancer. Results: Forty-nine of 9,012 male patients were carriers of G84E (0.5%). Thirty-one percent (n = 2,595) of participants had been diagnosed with cancer, including 51.1% of G84E carriers compared with just 30.6% of noncarriers (P = 0.004). G84E was most frequently observed among men with prostate cancer compared with men without cancer (P < 0.0001). However, the mutation was also more commonly observed in men with bladder cancer (P = 0.06) and leukemia (P = 0.01). G84E carriers were more likely to have a positive family history of prostate cancer in a first-degree relative compared to noncarriers (36.2% vs. 16.0%, P = 0.0003). Conclusions: Our study confirms the association between the HOXB13 G84E variant and prostate cancer and suggests a novel association between G84E and leukemia and a suggestive association with bladder cancer. Future investigation is warranted to confirm these associations in order to improve our understanding of the role of germline HOXB13 mutations in human cancer. Impact: The associations between HOXB13 and prostate, leukemia, and bladder suggest that this gene is important in carcinogenesis.

Original languageEnglish (US)
Pages (from-to)1366-1372
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Prostatic Neoplasms
Mutation
Leukemia
Neoplasms
Urinary Bladder Neoplasms
Medical History Taking
Germ-Line Mutation
Mutation Rate
Genes
Prostate
Carcinogenesis
Urinary Bladder
DNA

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies. / Beebe-Dimmer, Jennifer L.; Hathcock, Matthew; Yee, Cecilia; Okoth, Linda A.; Ewing, Charles M.; Isaacs, William B.; Cooney, Kathleen A.; Thibodeau, Stephen N.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 24, No. 9, 01.09.2015, p. 1366-1372.

Research output: Contribution to journalArticle

Beebe-Dimmer, Jennifer L. ; Hathcock, Matthew ; Yee, Cecilia ; Okoth, Linda A. ; Ewing, Charles M. ; Isaacs, William B. ; Cooney, Kathleen A. ; Thibodeau, Stephen N. / The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies. In: Cancer Epidemiology Biomarkers and Prevention. 2015 ; Vol. 24, No. 9. pp. 1366-1372.
@article{f2c3bf1cee2b4587bb40dddae6d94205,
title = "The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies",
abstract = "Background: A rare nonconservative substitution (G84E) in the HOXB13 gene has been shown to be associated with risk of prostate cancer. DNA samples from male patients included in the Mayo Clinic Biobank (MCB) were genotyped to determine the frequency of the G84E mutation and its association with various cancers. Methods: Subjects were genotyped using a custom TaqMan (Applied Biosystems) assay for G84E (rs138213197). In addition to donating a blood specimen, all MCB participants completed a baseline questionnaire to collect information on medical history and family history of cancer. Results: Forty-nine of 9,012 male patients were carriers of G84E (0.5{\%}). Thirty-one percent (n = 2,595) of participants had been diagnosed with cancer, including 51.1{\%} of G84E carriers compared with just 30.6{\%} of noncarriers (P = 0.004). G84E was most frequently observed among men with prostate cancer compared with men without cancer (P < 0.0001). However, the mutation was also more commonly observed in men with bladder cancer (P = 0.06) and leukemia (P = 0.01). G84E carriers were more likely to have a positive family history of prostate cancer in a first-degree relative compared to noncarriers (36.2{\%} vs. 16.0{\%}, P = 0.0003). Conclusions: Our study confirms the association between the HOXB13 G84E variant and prostate cancer and suggests a novel association between G84E and leukemia and a suggestive association with bladder cancer. Future investigation is warranted to confirm these associations in order to improve our understanding of the role of germline HOXB13 mutations in human cancer. Impact: The associations between HOXB13 and prostate, leukemia, and bladder suggest that this gene is important in carcinogenesis.",
author = "Beebe-Dimmer, {Jennifer L.} and Matthew Hathcock and Cecilia Yee and Okoth, {Linda A.} and Ewing, {Charles M.} and Isaacs, {William B.} and Cooney, {Kathleen A.} and Thibodeau, {Stephen N}",
year = "2015",
month = "9",
day = "1",
doi = "10.1158/1055-9965.EPI-15-0247",
language = "English (US)",
volume = "24",
pages = "1366--1372",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies

AU - Beebe-Dimmer, Jennifer L.

AU - Hathcock, Matthew

AU - Yee, Cecilia

AU - Okoth, Linda A.

AU - Ewing, Charles M.

AU - Isaacs, William B.

AU - Cooney, Kathleen A.

AU - Thibodeau, Stephen N

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background: A rare nonconservative substitution (G84E) in the HOXB13 gene has been shown to be associated with risk of prostate cancer. DNA samples from male patients included in the Mayo Clinic Biobank (MCB) were genotyped to determine the frequency of the G84E mutation and its association with various cancers. Methods: Subjects were genotyped using a custom TaqMan (Applied Biosystems) assay for G84E (rs138213197). In addition to donating a blood specimen, all MCB participants completed a baseline questionnaire to collect information on medical history and family history of cancer. Results: Forty-nine of 9,012 male patients were carriers of G84E (0.5%). Thirty-one percent (n = 2,595) of participants had been diagnosed with cancer, including 51.1% of G84E carriers compared with just 30.6% of noncarriers (P = 0.004). G84E was most frequently observed among men with prostate cancer compared with men without cancer (P < 0.0001). However, the mutation was also more commonly observed in men with bladder cancer (P = 0.06) and leukemia (P = 0.01). G84E carriers were more likely to have a positive family history of prostate cancer in a first-degree relative compared to noncarriers (36.2% vs. 16.0%, P = 0.0003). Conclusions: Our study confirms the association between the HOXB13 G84E variant and prostate cancer and suggests a novel association between G84E and leukemia and a suggestive association with bladder cancer. Future investigation is warranted to confirm these associations in order to improve our understanding of the role of germline HOXB13 mutations in human cancer. Impact: The associations between HOXB13 and prostate, leukemia, and bladder suggest that this gene is important in carcinogenesis.

AB - Background: A rare nonconservative substitution (G84E) in the HOXB13 gene has been shown to be associated with risk of prostate cancer. DNA samples from male patients included in the Mayo Clinic Biobank (MCB) were genotyped to determine the frequency of the G84E mutation and its association with various cancers. Methods: Subjects were genotyped using a custom TaqMan (Applied Biosystems) assay for G84E (rs138213197). In addition to donating a blood specimen, all MCB participants completed a baseline questionnaire to collect information on medical history and family history of cancer. Results: Forty-nine of 9,012 male patients were carriers of G84E (0.5%). Thirty-one percent (n = 2,595) of participants had been diagnosed with cancer, including 51.1% of G84E carriers compared with just 30.6% of noncarriers (P = 0.004). G84E was most frequently observed among men with prostate cancer compared with men without cancer (P < 0.0001). However, the mutation was also more commonly observed in men with bladder cancer (P = 0.06) and leukemia (P = 0.01). G84E carriers were more likely to have a positive family history of prostate cancer in a first-degree relative compared to noncarriers (36.2% vs. 16.0%, P = 0.0003). Conclusions: Our study confirms the association between the HOXB13 G84E variant and prostate cancer and suggests a novel association between G84E and leukemia and a suggestive association with bladder cancer. Future investigation is warranted to confirm these associations in order to improve our understanding of the role of germline HOXB13 mutations in human cancer. Impact: The associations between HOXB13 and prostate, leukemia, and bladder suggest that this gene is important in carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84941760614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941760614&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-15-0247

DO - 10.1158/1055-9965.EPI-15-0247

M3 - Article

C2 - 26108461

AN - SCOPUS:84941760614

VL - 24

SP - 1366

EP - 1372

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -